We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Test for P53 Mutations to Aid Biotech Researchers and Drug Developers

By LabMedica International staff writers
Posted on 19 Nov 2014
Print article
Image: A micrograph showing cells with abnormal P53 expression (brown) in a brain tumor (Photo courtesy of Wikimedia Commons).
Image: A micrograph showing cells with abnormal P53 expression (brown) in a brain tumor (Photo courtesy of Wikimedia Commons).
A biotech services company in the United Kingdom has launched an in-house service that utilizes a next generation sequencing test to identify mutations in the P53 tumor suppressor gene.

Cancer cells typically contain two types of mutations: mutations that cause uncontrolled growth and multiplication of cells, and other mutations that block the normal defenses that protect against unnatural growth. The P53 gene is in this second category and mutations in this gene contribute to about half of the cases of human cancer. In these mutants normal p53 protein function is blocked, and the protein is unable to stop multiplication of the damaged cell. If the cell has other mutations that cause uncontrolled growth, it will develop into a tumor.

To aid biotech researchers and drug developers by facilitating studies involving P53 mutations the Almac Group (Craigavon, UK) has launched a [US] Food and Drugs Administration CLIA (Clinical Laboratory Improvement Amendments)-validated next generation sequencing test for P53 mutations.

The test, which can be run on formalin fixed paraffin embedded (FFPE) specimens, was developed using Illumina (Little Chesterford, United Kingdom) next generation sequencing technology. The test covers all coding regions and upstream regulatory regions of P53 and provides detail on specified mutations as well as a significant amount of sequence data that allows the potential discovery of other clinically relevant mutations.

The test will be performed in Almac’s CLIA certified and CAP (College of American Pathologists) accredited clinical testing laboratory and is available now for general use. The test was specifically developed to support early phase trial enrichment studies and can be run with a one week turnaround time where required.

Prof. Paul Harkin, president of Almac’s diagnostic business unit, said, “We have developed and launched this test as a response to an obvious customer demand. P53 is an important oncogene that is linked to many cancers and there are a significant number of new therapies in the pharma pipeline for which P53 is being used as a biomarker. Next generation sequencing was an ideal approach for an assay of this complexity, and the Illumina technology is an excellent platform on which to deliver such a test.”

Related Links:

Almac Group
Illumina


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Unit-Dose Packaging solution
HLX
New
Urine Bone Markers Control
Lyphochek Urine Bone Markers Control
New
Hepato Fibrosis Assays
Hepato Fibrosis Assays

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: Schematic overview of maternal biomarker discovery using cell-free RNA during pregnancy (Photo courtesy of Circulation Research (2024). DOI: 10.1161/CIRCRESAHA.124.325024)

Maternal Blood Test Identifies Congenital Heart Diseases in Fetus

Each year, around 1,000 children are born with a single ventricle heart defect (SVHD), a condition where one of the heart's lower chambers is underdeveloped, too small, or missing a valve.... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image

AI-Based Method Shows Promise for Pathological Diagnosis of Hereditary Kidney Diseases

Alport syndrome is a hereditary kidney disorder characterized by kidney dysfunction, sensorineural hearing loss, and ocular abnormalities. Early in the disease, patients experience hematuria, which is... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.